How much can a multinational take before its social licence to operate in this country expires? How much corporate welfare is too much? We examine the case of Gilead Sciences and its “blockbuster” cure for hepatitis C. Like its Big Pharma peers, Gilead Sciences enjoys lavish taxpayer subsidies via the Pharmaceutical Benefits Scheme (PBS). It … Continue reading The Gilead and the taxpayer Odyssey